Literature DB >> 7533121

Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C.

J M Barrera1, M Bruguera, M G Ercilla, C Gil, R Celis, M P Gil, M del Valle Onorato, J Rodés, A Ordinas.   

Abstract

Persistent viremia after clinical or subclinical hepatitis C virus (HCV) infection is believed to occur in patients with chronic hepatitis C, but little is known about the duration of HCV replication in patients with acute hepatitis who have recovered or the relation of HCV viremia with the kinetics of antibodies to HCV (anti-HCV). We tested HCV-RNA and anti-HCV in serial serum samples from 41 patients with posttransfusion non-A, non-B hepatitis, followed for an average of 6 years after transfusion. Serum HCV-RNA was measured by nested polymerase chain reaction, which used primers from the 5' untranslated region of the HCV genome. Anti-HCV were tested with first- and second-generation enzyme-linked immunosorbent assays (ELISA 1 and ELISA 2), and with a second-generation recombinant immunoblot assay. Of the 41 patients, 10 recovered and 31 progressed to chronic liver disease. HCV-RNA was detected in serum before or simultaneously with the onset of hepatitis in all cases, and lasted between 2 and 6 weeks in 5 of the 10 patients who recovered, whereas it persisted for the entire follow-up period in every case with chronic hepatitis and in the remaining 5 patients with self-limiting hepatitis. Anti-HCV were detected with ELISA 2 in the first serum sample, with raised serum transaminases in 57% of patients, but in only 6% with ELISA 1. In the sample obtained 1 month after the onset of hepatitis, anti-HCV were detected with ELISA 2 in 94% of patients, but in 34% with the ELISA 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533121

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

1.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

2.  Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.

Authors:  Pn Rao; Abraham Koshy; Jacob Philip; Narayanan Premaletha; Joy Varghese; Krishnasamy Narayanasamy; Samir Mohindra; Nitin Vikas Pai; Manoj Kumar Agarwal; Ashoknanda Konar; Hasmukh B Vora
Journal:  World J Hepatol       Date:  2014-07-27

3.  Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans.

Authors:  Erik J Groessl; Kimberly R Weingart; Robert M Kaplan; Jack A Clark; Allen L Gifford; Samuel B Ho
Journal:  J Gen Intern Med       Date:  2008-09-20       Impact factor: 5.128

4.  High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.

Authors:  W Vogel; I Graziadei; F Umlauft; C Datz; F Hackl; S Allinger; K Grünewald; J Patsch
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.

Authors:  Daiki Miki; Hidenori Ochi; C Nelson Hayes; Hiromi Abe; Tadahiko Yoshima; Hiroshi Aikata; Kenji Ikeda; Hiromitsu Kumada; Joji Toyota; Takashi Morizono; Tatsuhiko Tsunoda; Michiaki Kubo; Yusuke Nakamura; Naoyuki Kamatani; Kazuaki Chayama
Journal:  Nat Genet       Date:  2011-07-03       Impact factor: 38.330

6.  Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy.

Authors:  Douglas L Nguyen; Ke-Qin Hu
Journal:  N Am J Med Sci (Boston)       Date:  2014

7.  Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population.

Authors:  Yaser Dahlan; Hafiz-Mughees Ather; Majid Al-ahmadi; Faisal Batwa; Waleed Al-hamoudi
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

8.  Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance.

Authors:  E Spada; A Mele; A Berton; L Ruggeri; L Ferrigno; A R Garbuglia; M P Perrone; G Girelli; P Del Porto; E Piccolella; M U Mondelli; P Amoroso; R Cortese; A Nicosia; A Vitelli; A Folgori
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

9.  IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Authors:  Masaya Sato; Naoya Kato; Ryosuke Tateishi; Ryosuke Muroyama; Norie Kowatari; Wenwen Li; Kaku Goto; Motoyuki Otsuka; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-05-22       Impact factor: 7.527

10.  Changes in liver enzymes after surgery in anti-hepatitis C virus-positive patients.

Authors:  Saburo Murakami; Katsuhiko Okubo; Yoshitaka Tsuji; Hideto Sakata; Takehiro Takahashi; Masataka Kikuchi; Renzo Hirayama
Journal:  World J Surg       Date:  2004-06-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.